Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking ...

A newly approved blood test can help rule out some cases based on the amount of amyloid in the brain. A neurology professor ...

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

Scientists hail ‘very exciting’ findings that explain why Alzheimer’s patients forget their loved ones, and say drugs are ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...